VivoSeq
Other

Concurrent Chemoradiotherapy

0

Pipeline Programs↗

15

Active Trials↗

2

Companies Involved↗

Concurrent Chemoradiotherapy is an early-stage landscape with 0 programs across 2 companies. The most active players are Sanofi, Genfleet Therapeutics (Shanghai) Inc..

Intelligence

Pipeline Metrics

Competitive Density

32/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

50/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

0 programs

PreclinicalG

Genfleet Therapeutics (Shanghai) Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

41

clinical trials

Unknown status18 · 44%
Recruiting6 · 15%
Active, not recruiting5 · 12%
Completed4 · 10%
Not yet recruiting4 · 10%
Terminated3 · 7%
Other1 · 2%

Clinical Trials

Trial Activity

41 trials

WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC
Recruiting·—·Phase 2·NCT05351320·40 enrolled
Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.
Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06452602·60 enrolled
Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients
Recruiting·—·Phase 2·NCT05443646·55 enrolled
Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC
Recruiting·FFujian Medical University Union Hospital·Phase 2·NCT06510660·48 enrolled
Sodium Glycididazole Reduces the Adverse Reactions of Concurrent Chemoradiotherapy
Recruiting·—·Phase 2·NCT06667622·40 enrolled
Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06341595·40 enrolled
PD-1 Inhibitor INCMGA00012 as Consolidation Therapy After Definitive Concurrent Chemoradiotherapy
Active, not recruiting·—·Phase 2·NCT04494009·110 enrolled
Concurrent Chemoradiotherapy With or Without Metronomic Capecitabine in High-Risk T1-2N1M0 NPC
Active, not recruiting·—·Phase 3·NCT07248670·252 enrolled
The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC
Active, not recruiting·SSun Yat-sen University·Phase 2·NCT06139419·114 enrolled
Cadonilimab(AK104) Plus Concurrent Chemoradiotherapy in Patients With Locally Advanced, Unresectable, Stage III NSCLC
Active, not recruiting·FFudan University·Phase 2·NCT06448910·41 enrolled
Consolidation Chemotherapy for Locally Advanced Mid or Low Rectal Cancer After Neoadjuvant Concurrent Chemoradiotherapy
Active, not recruiting·KKyung Hee University Hospital at Gangdong·Phase 3·NCT02843191·358 enrolled
Neoadjuvant Chemo-immunotherapy Followed by Concurrent Chemoradiotherapy and Immunotherapy in LACC
Not yet recruiting·RRenJi Hospital·Phase 2·NCT06916117·30 enrolled
Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab
Not yet recruiting·HHarbin Medical University·Phase 2·NCT06304545·48 enrolled
The Study of Envafolimab Combined With Concurrent Chemoradiotherapy In LS-SCLC
Not yet recruiting·—·Phase 2·NCT05904015·80 enrolled
Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD
Not yet recruiting·PPeking University Cancer Hospital & Institute·Phase 2·NCT07357532·44 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)